Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

China’s retail sales rose by 4.0% in the January-February period from a year ago, in line with Reuters estimates.

Global private equity and venture capital deal value reached $37.93 billion in February, up 26.6% from January, according to ...

BLACKSTONE is buying a company that helps drugmakers run clinical trials in Japan, adding to growing interest from private equity firms in the health needs of the nation’s ageing population. Read more ...

Blackstone Inc. is buying a company that helps drugmakers run clinical trials in Japan, adding to growing interest from ...

Kioxia Holdings is backed by private equity firm Bain Capital and electronics conglomerate ... Shares in Japanese conglomerate Mitsubishi Heavy Industries gained as much 10.52% on Monday in ...

Bain Capital said it will buy Mitsubishi Chemical’s pharma business for $3.37 billion. Sanofi and CD&R signed an Opella share purchase agreement. Biogen partnered with Stoke Therapeutics on a drug for ...

February 7, 2025 Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4 billion U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 ...

Last month, Bain Capital triumphed in a bidding war to acquire Japan’s Mitsubishi Tanabe Pharma for $3.3 billion, carving it out from parent company Mitsubishi Chemical Group.